Capricor Therapeutics Inc (NASDAQ:CAPR) Short Interest Down 30.4% in September

Capricor Therapeutics Inc (NASDAQ:CAPR) saw a large drop in short interest in the month of September. As of September 30th, there was short interest totalling 5,240,000 shares, a drop of 30.4% from the September 15th total of 7,530,000 shares. Based on an average trading volume of 2,450,000 shares, the short-interest ratio is presently 2.1 days.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on CAPR. HC Wainwright reiterated a “buy” rating and set a $40.00 price objective on shares of Capricor Therapeutics in a research report on Wednesday. Maxim Group raised their target price on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, September 25th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $8.00 price objective on shares of Capricor Therapeutics in a research note on Friday, September 20th. Finally, Oppenheimer reissued an “outperform” rating and set a $15.00 target price on shares of Capricor Therapeutics in a research note on Monday, September 23rd. One analyst has rated the stock with a sell rating and five have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $22.60.

Capricor Therapeutics Stock Up 3.7 %

Shares of CAPR stock traded up $0.63 on Friday, hitting $17.77. The stock had a trading volume of 4,593,738 shares, compared to its average volume of 1,081,583. The company has a market cap of $568.27 million, a PE ratio of -20.43 and a beta of 4.01. The business has a 50 day moving average price of $7.44 and a 200 day moving average price of $6.07. Capricor Therapeutics has a one year low of $2.68 and a one year high of $21.98.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. The business had revenue of $3.97 million for the quarter, compared to analysts’ expectations of $4.51 million. Equities research analysts expect that Capricor Therapeutics will post -1.13 EPS for the current year.

Insiders Place Their Bets

In other news, major shareholder Shinyaku Co Ltd Nippon bought 2,798,507 shares of the firm’s stock in a transaction on Friday, September 20th. The shares were bought at an average price of $5.36 per share, for a total transaction of $14,999,997.52. Following the purchase, the insider now owns 7,090,351 shares in the company, valued at approximately $38,004,281.36. The trade was a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 12.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On Capricor Therapeutics

Large investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its position in Capricor Therapeutics by 17.2% in the 1st quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock worth $9,274,000 after purchasing an additional 200,499 shares in the last quarter. Marshall Wace LLP acquired a new position in Capricor Therapeutics in the 2nd quarter valued at $426,000. Renaissance Technologies LLC raised its stake in Capricor Therapeutics by 158.7% in the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock valued at $656,000 after purchasing an additional 84,350 shares during the last quarter. Rhumbline Advisers acquired a new position in Capricor Therapeutics in the 2nd quarter valued at $147,000. Finally, Bank of New York Mellon Corp raised its stake in Capricor Therapeutics by 12.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock valued at $381,000 after purchasing an additional 9,040 shares during the last quarter. Hedge funds and other institutional investors own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.